Melanotan-2 (10mg)

MC1R-Mediated Melanogenesis and Photoprotection

MC1R / cAMP / PKA / MITF Cascade — MT-II binds MC1R on melanocytes with high affinity (Ki = 0.67 nM), activating the Gs-protein/adenylyl cyclase/cAMP signaling cascade. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB, driving upregulation of microphthalmia-associated transcription factor (MITF). MITF in turn drives expression of melanogenic enzymes — tyrosinase, TRP-1, and TRP-2/DCT — catalyzing conversion of tyrosine to photoprotective eumelanin via DOPA and dopaquinone intermediates. The pathway preferentially produces eumelanin over phototoxic pheomelanin. MC1R activation also enhances nucleotide excision repair (NER) of UV-induced DNA damage and activates Nrf2-dependent antioxidant defense mechanisms through cAMP-dependent pathways (Mun et al., 2023).

MC4R-Mediated Hypothalamic and Metabolic Signaling

PVN / LH / Sympathetic Outflow — MT-II's cyclic structure and moderate lipophilicity (partition coefficient 2.82 at pH 7.35) enable blood-brain barrier penetration. MC4R is predominantly expressed in the hypothalamic paraventricular nucleus (PVN), lateral hypothalamus, brainstem, and spinal cord. MC4R activation increases sympathetic nervous system activity, upregulates uncoupling protein 1 (UCP1) in brown adipose tissue (thermogenesis), and enhances peripheral glucose disposal by upregulating GLUT4 mRNA expression in skeletal muscle ~3-fold (Heijboer et al., 2005). Peripheral MT-II reduces adipose tissue compartments through lipid mobilization and sympathetic activation of white adipose tissue — pair-fed control animals losing equivalent body mass retained significantly more adipose tissue than MT-II-treated animals, indicating direct lipolytic mechanisms beyond caloric restriction (Strader et al., 2007).

Neuroprotection via NF-κB Modulation

NF-κB / TNF-α / Schwann Cell Signaling — MT-II modulates NF-κB-mediated transcription in neural, glial, and endothelial cells, reducing pro-inflammatory agent production including TNF-α and IFN-γ after injury. This mechanism underlies neuroprotective effects demonstrated across sciatic nerve crush injury recovery (bell-shaped dose-response at 20 µg/kg per 48h), cisplatin-induced toxic neuropathy protection, brain ischemia neuroprotection with broad therapeutic time window, and neuronal rescue from excitotoxic insults. Cai & Hruby (2016) documented inhibition of TNF-α and IFN-γ-induced NF-κB activation in Schwann cells as a peripheral nerve regeneration mechanism.

Anti-Atherosclerotic Vascular Effects

Macrophage M2 Polarization / Endothelial NO Signaling — Rinne et al. (2014) demonstrated MT-II shifts resident plaque macrophages toward anti-inflammatory M2 phenotypes, reduces metabolic activity in atherosclerotic plaques (18F-FDG uptake), and enhances endothelium-dependent relaxation and nitric oxide-mediated vasodilation. These vascular benefits occurred independently of metabolic parameters or plasma cholesterol, confirming direct anti-inflammatory mechanisms. Chronic melanocortin-3/4 receptor activation has also been shown to increase blood pressure in preclinical models, indicating complex cardiovascular pharmacology (do Carmo et al., 2011).

Mast Cell Activation (Off-Target Effect)

MRGPRB2 / Histamine H1 Receptor — MT-II activates mast cells through both MRGPRB2-dependent and MRGPRB2-independent pathways (Jain et al., 2018), triggering histamine release that binds H1 receptors and produces dose-dependent hypothermia. This effect was abolished in mast cell-deficient mice and substantially reduced by H1 receptor blockade, explaining the flushing, nausea, and temperature changes observed as common off-target effects in MT-II research studies.